天域生物拟向实控人方定增 连亏5年一实控人“退场”

Core Viewpoint - Tianyu Bio (603717.SH) has announced a plan to issue A-shares to a specific entity controlled by its actual controller, Luo Weiguo, to raise funds for working capital and debt repayment [1][2]. Group 1: Share Issuance Details - The share issuance price is set at 6.55 CNY per share, which is 80% of the average trading price over the last 20 trading days [1]. - The maximum number of shares to be issued is 71,028,297, not exceeding 30% of the total share capital before the issuance [1]. - The total funds raised are expected to be no more than 465.2353 million CNY, which will be used entirely for working capital and debt repayment after deducting issuance costs [1]. Group 2: Changes in Control - Luo Weiguo currently holds 12.84% of the company's shares and will maintain control after the issuance, with voting rights expected to increase to 29.98% [1][2]. - The actual controller's status has changed, with Luo Weiguo now being the sole controller following the termination of the joint action agreement with Shi Dongwei [2][3]. - Shi Dongwei has resigned from the position of president and has relinquished all voting rights associated with his shares, reducing his voting rights to 0% [3][4]. Group 3: Financial Performance - For the first half of 2025, the company anticipates a net profit attributable to shareholders of 8 million to 12 million CNY, representing an increase of 28.44% to 92.66% compared to the previous year [5]. - The company has reported continuous losses over the past five years, with a net profit of -107.36 million CNY in 2024, an improvement from -461.64 million CNY in 2023 [5][7]. - The operating revenue for 2024 was 802 million CNY, a year-on-year increase of 19.55% [7].